PriceTargets.com logo

PAVmed - PAVM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.42
  • Forecasted Upside: 780.33 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.62 As of 12/7/2022 02:12 PM ET
▲ +0.0053 (0.87%)

This chart shows the closing price for PAVM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PAVmed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PAVM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PAVM

Analyst Price Target is $5.42
▲ +780.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for PAVmed in the last 3 months. The average price target is $5.42, with a high forecast of $8.25 and a low forecast of $3.00. The average price target represents a 780.33% upside from the last price of $0.62.

This chart shows the closing price for PAVM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in PAVmed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/24/2022Ascendiant Capital MarketsSet Target$8.25Low
8/17/2022Lake Street CapitalLower TargetBuy$7.00 ➝ $5.00Low
6/9/2022Ascendiant Capital MarketsLower Target$9.00High
5/17/2022Maxim GroupLower TargetNA$3.00Low
4/7/2022Maxim GroupLower Target$10.00 ➝ $4.00High
2/12/2022Cantor FitzgeraldReiterated RatingOverweightHigh
8/13/2021Maxim GroupReiterated RatingBuy$8.00High
7/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
6/4/2021Maxim GroupReiterated RatingBuy$8.00High
3/29/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00High
2/22/2021Lake Street CapitalBoost TargetBuy$5.00 ➝ $9.00High
11/5/2020Ascendiant Capital MarketsInitiated CoverageBuy$5.00Medium
10/13/2020Lake Street CapitalInitiated CoverageBuy$5.00Medium
5/30/2020Maxim GroupReiterated RatingBuy$5.00Low
5/22/2020Maxim GroupReiterated RatingBuy$5.00N/A
4/17/2020Maxim GroupReiterated RatingBuy$5.00High
2/26/2020Maxim GroupReiterated RatingBuy$5.00High
11/22/2019Maxim GroupReiterated RatingBuy$3.00Low
8/16/2019Maxim GroupSet TargetBuy$3.00Low
5/23/2019Maxim GroupReiterated RatingBuyHigh
4/7/2019Maxim GroupReiterated RatingBuyMedium
1/14/2019Maxim GroupReiterated RatingBuy$3.00Medium
6/28/2018Maxim GroupInitiated CoverageBuy$5.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

-0.76 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2022
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/8/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/7/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
12/7/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
PAVmed logo
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Read More

Today's Range

Now: $0.62
Low: $0.60
High: $0.64

50 Day Range

MA: $0.95
Low: $0.65
High: $1.24

52 Week Range

Now: $0.62
Low: $0.58
High: $3.66

Volume

2,704 shs

Average Volume

863,302 shs

Market Capitalization

$55.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of PAVmed?

The following Wall Street sell-side analysts have issued research reports on PAVmed in the last twelve months: Ascendiant Capital Markets, Cantor Fitzgerald, Lake Street Capital, and Maxim Group.
View the latest analyst ratings for PAVM.

What is the current price target for PAVmed?

3 Wall Street analysts have set twelve-month price targets for PAVmed in the last year. Their average twelve-month price target is $5.42, suggesting a possible upside of 780.3%. Ascendiant Capital Markets has the highest price target set, predicting PAVM will reach $8.25 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for PAVmed in the next year.
View the latest price targets for PAVM.

What is the current consensus analyst rating for PAVmed?

PAVmed currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PAVM will outperform the market and that investors should add to their positions of PAVmed.
View the latest ratings for PAVM.

What other companies compete with PAVmed?

Other companies that are similar to PAVmed include Pro-Dex, Retractable Technologies, Cytosorbents, Apyx Medical and Isoray. Learn More about companies similar to PAVmed.

How do I contact PAVmed's investor relations team?

PAVmed's physical mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company's listed phone number is (212) 949-4319 and its investor relations email address is [email protected] The official website for PAVmed is www.pavmed.com. Learn More about contacing PAVmed investor relations.